vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Arteris, Inc. (AIP). Click either name above to swap in a different company.
Arteris, Inc. is the larger business by last-quarter revenue ($20.1M vs $10.7M, roughly 1.9× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs -42.2%, a 65.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 30.0%). Over the past eight quarters, Arteris, Inc.'s revenue compounded faster (24.7% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Arteris, Inc. is a multinational technology company headquartered in Campbell, California. It develops the network-on-chip (NoC) IP and system-on-chip (SoC) integration automation software that is used to create semiconductor chip and chiplet designs for a variety of devices, particularly in automotive electronics, artificial intelligence, machine learning, enterprise computing, communications, consumer, industrial, and aerospace & defense markets. The company specializes in the development a...
ABUS vs AIP — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $20.1M |
| Net Profit | $2.5M | $-8.5M |
| Gross Margin | — | 90.8% |
| Operating Margin | 13.9% | -42.0% |
| Net Margin | 23.5% | -42.2% |
| Revenue YoY | 522.2% | 30.0% |
| Net Profit YoY | 112.7% | -3.7% |
| EPS (diluted) | $0.01 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.1M | ||
| Q3 25 | — | $17.4M | ||
| Q2 25 | $10.7M | $16.5M | ||
| Q1 25 | — | $16.5M | ||
| Q4 24 | — | $15.5M | ||
| Q3 24 | — | $14.7M | ||
| Q2 24 | — | $14.6M | ||
| Q1 24 | — | $12.9M |
| Q4 25 | — | $-8.5M | ||
| Q3 25 | — | $-9.0M | ||
| Q2 25 | $2.5M | $-9.1M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-8.2M | ||
| Q3 24 | — | $-7.7M | ||
| Q2 24 | — | $-8.3M | ||
| Q1 24 | — | $-9.4M |
| Q4 25 | — | 90.8% | ||
| Q3 25 | — | 89.9% | ||
| Q2 25 | — | 89.4% | ||
| Q1 25 | — | 90.8% | ||
| Q4 24 | — | 89.8% | ||
| Q3 24 | — | 90.1% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 88.7% |
| Q4 25 | — | -42.0% | ||
| Q3 25 | — | -50.1% | ||
| Q2 25 | 13.9% | -50.0% | ||
| Q1 25 | — | -46.6% | ||
| Q4 24 | — | -45.9% | ||
| Q3 24 | — | -53.8% | ||
| Q2 24 | — | -51.1% | ||
| Q1 24 | — | -70.5% |
| Q4 25 | — | -42.2% | ||
| Q3 25 | — | -51.6% | ||
| Q2 25 | 23.5% | -55.3% | ||
| Q1 25 | — | -49.1% | ||
| Q4 24 | — | -53.0% | ||
| Q3 24 | — | -52.2% | ||
| Q2 24 | — | -57.2% | ||
| Q1 24 | — | -72.6% |
| Q4 25 | — | $-0.19 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | $0.01 | $-0.22 | ||
| Q1 25 | — | $-0.20 | ||
| Q4 24 | — | $-0.19 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.22 | ||
| Q1 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $33.9M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $-14.6M |
| Total Assets | $103.3M | $115.0M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $33.9M | ||
| Q3 25 | — | $39.0M | ||
| Q2 25 | $37.4M | $38.0M | ||
| Q1 25 | — | $42.3M | ||
| Q4 24 | — | $43.8M | ||
| Q3 24 | — | $48.7M | ||
| Q2 24 | — | $45.8M | ||
| Q1 24 | — | $44.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-14.6M | ||
| Q3 25 | — | $-11.4M | ||
| Q2 25 | $83.0M | $-7.5M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $9.5M |
| Q4 25 | — | $115.0M | ||
| Q3 25 | — | $107.7M | ||
| Q2 25 | $103.3M | $106.9M | ||
| Q1 25 | — | $98.3M | ||
| Q4 24 | — | $106.1M | ||
| Q3 24 | — | $97.7M | ||
| Q2 24 | — | $96.4M | ||
| Q1 24 | — | $101.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $3.2M |
| Free Cash FlowOCF − Capex | — | $3.0M |
| FCF MarginFCF / Revenue | — | 15.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | -6.24× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.2M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | $-15.7M | $-2.5M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $-2.6M | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $311.0K | ||
| Q1 24 | — | $477.0K |
| Q4 25 | — | $3.0M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $1.1M | ||
| Q2 24 | — | $264.0K | ||
| Q1 24 | — | $281.0K |
| Q4 25 | — | 15.1% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | -17.2% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | — | -17.3% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | 1.8% | ||
| Q1 24 | — | 2.2% |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 1.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
AIP
| License And Maintenance | $17.5M | 87% |
| Variable Royalties And Other | $2.6M | 13% |
